中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

11 records (took 0.015 seconds)

    IMMUNOGENS DERIVED FROM SARS-COV2 SPIKE PROTEIN
    1.
    发明公开
    IMMUNOGENS DERIVED FROM SARS-COV2 SPIKE PROTEIN 审中-公开

    公开(公告)号：US20230322867A1

    公开(公告)日：2023-10-12

    申请号：US18006689

    申请日：2021-07-22

    Applicant: AMGEN INC.

    Inventor： Fernando GARCES ,  Zhulun WANG ,  Timothy RILEY

    IPC: C07K14/165 ,  C12N15/85 ,  C07K16/10

    CPC classification number: C07K14/165 ,  C07K16/10 ,  C12N15/85 ,  A61K2039/505

    Abstract: The present invention relates to severe acute respiratory syndrome coronavirus 2 (“SARS-CoV2”) immunogens useful for the generation of therapeutic antibodies and vaccine development. Such therapeutic antibodies include human antibodies and antigen-binding portions thereof that specifically bind to human SARS-CoV2 S protein, and that function to neutralize SARS-CoV2. The present invention also relates to methods of generating antibodies and antigen-binding portions thereof that specifically bind to human SARS-CoV2 S protein.

    NOVEL LINKERS OF MULTISPECIFIC ANTIGEN BINDING DOMAINS
    2.
    发明公开
    NOVEL LINKERS OF MULTISPECIFIC ANTIGEN BINDING DOMAINS 审中-公开

    公开(公告)号：US20240002545A1

    公开(公告)日：2024-01-04

    申请号：US18252442

    申请日：2021-11-09

    Applicant: AMGEN INC.

    Inventor： Timothy RILEY ,  Fernando GARCES ,  Zhulun WANG ,  Bram Estes ,  Darren L. Bates

    IPC: C07K16/46

    CPC classification number: C07K16/468 ,  C07K2317/55 ,  C07K2317/64 ,  C07K2317/31

    Abstract: The ability to generate a single antibody-based construct that can recognize multiple targets simultaneously, is paramount to advance many therapeutics candidates to clinic. Often, this implies extensive protein design with vary degrees of success. In the case of multispecific antibodies, the driving of the HC/LC pairing in the Fab region represents one of the most difficult challenges yet in the field of multispecific engineering. Described here is the discovery of a new single chain Fab module that utilizes a novel linker between VL-CL and VH-CH1 domains which will further enable the production of multispecifics.

    ENGINEERING THE HINGE REGION TO DRIVE ANTIBODY DIMERIZATION
    5.
    发明申请
    ENGINEERING THE HINGE REGION TO DRIVE ANTIBODY DIMERIZATION 有权

    公开(公告)号：US20220235148A1

    公开(公告)日：2022-07-28

    申请号：US17615555

    申请日：2020-05-29

    Applicant: Amgen Inc.

    Inventor： Fernando GARCES ,  Zhulun WANG

    IPC: C07K16/46 ,  C07K16/18

    Abstract: The clinical potential of multispecific antibodies like bispecific and trispecific antibodies shows great promise for targeting complex diseases. However, the generation of those molecules presents great challenges as in many cases it is desired to specifically drive the specific pairing of multiple polypeptide chains that are present in solutions. In the case of the heavy chains, there are two main regions that form a dimer interface. One of them is the CH3 region, which has been widely exploited by inserting either charge-pair mutations (CPMs) to steer the dimer interface or inserting large bulky residues into cavities (Knob in Hole) to physically favor and disfavor the dimer formation. However, each of these strategies may not be applied to every molecule and therefore there is the need for more tools. Here, we describe the engineering of the Hinge region with a small number of mutations that are capable to alone successfully drive the heavy chain dimerization.

    ANTIGEN BINDING PROTEINS WITH NON-CANONICAL DISULFIDE IN FAB REGION
    9.
    发明公开
    ANTIGEN BINDING PROTEINS WITH NON-CANONICAL DISULFIDE IN FAB REGION 审中-公开

    公开(公告)号：US20230322955A1

    公开(公告)日：2023-10-12

    申请号：US18042267

    申请日：2021-08-19

    Applicant: AMGEN INC.

    Inventor： Fernando GARCES ,  Zhulun WANG

    IPC: C07K16/46

    CPC classification number: C07K16/468 ,  C07K2317/31 ,  C07K2317/55 ,  C07K2317/51 ,  C07K2317/54

    Abstract: The ability to generate a single antibody-based construct that can recognize multiple targets simultaneously, is paramount to advance many therapeutics candidates to clinic. Often, this implies extensive protein design with vary degrees of success. In the case of multispecific antibodies, the driving of the HC/LC pairing in the Fab region represents one of the most difficult challenges yet in the field of multispecific engineering. Described here is the discovery of a new placement for a non-canonical disulfide bond and as such the generation of an asymmetric cysteine interface between two Fabs present in the same molecule which will further enable the production of multispecifics.

    NOVEL MULTISPECIFIC ANTIBODY FORMAT
    10.
    发明申请
    NOVEL MULTISPECIFIC ANTIBODY FORMAT 有权

    公开(公告)号：US20230047631A1

    公开(公告)日：2023-02-16

    申请号：US17778361

    申请日：2020-11-18

    Applicant: AMGEN INC.

    Inventor： Fernando GARCES ,  Zhulun WANG

    IPC: C07K16/46

    Abstract: The present invention relates to novel multispecific antigen binding proteins that are capable of binding to multiple targets. Pharmaceutical compositions comprising the multispecific antigen binding proteins as well as methods for producing them are also disclosed.

Patent Agency Ranking